These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 21072165)

  • 1. High-affinity inhibitors of human NAD-dependent 15-hydroxyprostaglandin dehydrogenase: mechanisms of inhibition and structure-activity relationships.
    Niesen FH; Schultz L; Jadhav A; Bhatia C; Guo K; Maloney DJ; Pilka ES; Wang M; Oppermann U; Heightman TD; Simeonov A
    PLoS One; 2010 Nov; 5(11):e13719. PubMed ID: 21072165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-activity relationship studies and biological characterization of human NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase inhibitors.
    Duveau DY; Yasgar A; Wang Y; Hu X; Kouznetsova J; Brimacombe KR; Jadhav A; Simeonov A; Thomas CJ; Maloney DJ
    Bioorg Med Chem Lett; 2014 Jan; 24(2):630-5. PubMed ID: 24360556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by cyclooxygenase inhibitors and chemopreventive agents.
    Cho H; Tai HH
    Prostaglandins Leukot Essent Fatty Acids; 2002 Dec; 67(6):461-5. PubMed ID: 12468268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of glutamine 148 of human 15-hydroxyprostaglandin dehydrogenase in catalytic oxidation of prostaglandin E2.
    Cho H; Huang L; Hamza A; Gao D; Zhan CG; Tai HH
    Bioorg Med Chem; 2006 Oct; 14(19):6486-91. PubMed ID: 16828555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Key NAD+-binding residues in human 15-hydroxyprostaglandin dehydrogenase.
    Cho H; Hamza A; Zhan CG; Tai HH
    Arch Biochem Biophys; 2005 Jan; 433(2):447-53. PubMed ID: 15581601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thiazolidinediones as a novel class of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase inhibitors.
    Cho H; Tai HH
    Arch Biochem Biophys; 2002 Sep; 405(2):247-51. PubMed ID: 12220539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding human 15-hydroxyprostaglandin dehydrogenase binding with NAD+ and PGE2 by homology modeling, docking and molecular dynamics simulation.
    Hamza A; Cho H; Tai HH; Zhan CG
    Bioorg Med Chem; 2005 Jul; 13(14):4544-51. PubMed ID: 15908215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-Terminal region of human NAD+-dependent 15-hydroxyprostaglandin dehydrogenase is involved in the interaction with prostaglandin substrates.
    Zhou H; Yan F; Tai HH
    Eur J Biochem; 2001 Jun; 268(12):3368-74. PubMed ID: 11422365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of 15-hydroxyprostaglandin dehydrogenase catalytic reaction mechanism by molecular dynamics simulations.
    Al-Najjar BO
    J Mol Graph Model; 2018 Mar; 80():190-196. PubMed ID: 29414038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Threonine 188 is critical for interaction with NAD+ in human NAD+-dependent 15-hydroxyprostaglandin dehydrogenase.
    Zhou H; Tai HH
    Biochem Biophys Res Commun; 1999 Apr; 257(2):414-7. PubMed ID: 10198228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Critical residues for the coenzyme specificity of NAD+-dependent 15-hydroxyprostaglandin dehydrogenase.
    Cho H; Oliveira MA; Tai HH
    Arch Biochem Biophys; 2003 Nov; 419(2):139-46. PubMed ID: 14592457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ROS-Mediated 15-Hydroxyprostaglandin Dehydrogenase Degradation via Cysteine Oxidation Promotes NAD
    Wang W; Hu Y; Wang X; Wang Q; Deng H
    Cell Chem Biol; 2018 Mar; 25(3):255-261.e4. PubMed ID: 29307841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NAD+-linked 15-hydroxyprostaglandin dehydrogenase: structure and biological functions.
    Tai HH; Cho H; Tong M; Ding Y
    Curr Pharm Des; 2006; 12(8):955-62. PubMed ID: 16533162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crystal structure of the PIM2 kinase in complex with an organoruthenium inhibitor.
    Bullock AN; Russo S; Amos A; Pagano N; Bregman H; Debreczeni JE; Lee WH; von Delft F; Meggers E; Knapp S
    PLoS One; 2009 Oct; 4(10):e7112. PubMed ID: 19841674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 15-Hydroxyprostaglandin dehydrogenase.
    Ensor CM; Tai HH
    J Lipid Mediat Cell Signal; 1995 Oct; 12(2-3):313-9. PubMed ID: 8777575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The wound-healing effect of 7,3',4'-trimethoxyflavone through increased levels of prostaglandin E
    Sun KH; Karna S; Moon YS; Cho H; Choi CH
    Biotechnol Lett; 2017 Oct; 39(10):1575-1582. PubMed ID: 28664315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endogenous inhibitors of human placental prostaglandin dehydrogenase.
    Mibe M; Nagai K; Oshige T; Mori N
    Prostaglandins Leukot Essent Fatty Acids; 1992 Jul; 46(3):241-5. PubMed ID: 1508959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Control of the intracellular levels of prostaglandin E₂ through inhibition of the 15-hydroxyprostaglandin dehydrogenase for wound healing.
    Choi D; Piao YL; Wu Y; Cho H
    Bioorg Med Chem; 2013 Aug; 21(15):4477-84. PubMed ID: 23791868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on 15-hydroxyprostaglandin dehydrogenase with various prostaglandin analogues.
    Ohno H; Morikawa Y; Hirata F
    J Biochem; 1978 Dec; 84(6):1485-94. PubMed ID: 216666
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.